$Candel Therapeutics (CADL.US)$ This is my opinion, its Phas...
$Candel Therapeutics (CADL.US)$ This is my opinion, its Phase III study reached the main endpoint, which is a world of difference from Sava not reaching the endpoint. The survival rate of prostate cancer patients using their drug reached 70%. If true, it will not only be a victory for scientists, but also a victory for humanity in conquering prostate cancer. After FDA approval, the stock price will skyrocket. The current price drop due to fundraising is temporary, so buying on dips is the best strategy. In addition, many large institutions listed publicly have bought and held this month.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
